Acute promyelocytic leukemia (APL) is characterized by chromosomal rearrangements involving 17q21 disrupting the gene encoding retinoic acid receptor alpha (RARa), a transcription factor implicated in regulation of normal myelopoiesis. To date, five different fusion partners of RARa have been identified, with PML being most commonly involved as a result of the t(15;17)(q22;q12-21) translocation. In contrast to RARa, which functions as a transcriptional activator at physiological levels of its ligand retinoic acid (RA), the APL-associated fusion proteins act as transcriptional repressors due to preferential binding of corepressor complexes and recruitment of histone deacetylases (HDACs). Treatment of APL blasts harboring the PML-RARa oncoprotein with pharmacological levels of ATRA induces a conformational change in the fusion protein leading to displacement of corepressor complexes in favor of coactivators leading to histone acetylation and transcriptional activation, contributing to relief in the block in myeloid differentiation (reviewed in Mistry et al With more detailed understanding of the molecular pathogenesis of APL, there has been considerable interest to determine whether agents that inhibit HDAC activity could be of benefit to patients with this disease. In this regard, preclinical data have been encouraging, with HDAC inhibitors (HDACIs) such as trichostatin A (TSA) shown to potentiate ATRA-induced differentiation of the PML-RARa-positive NB4 cell line. 2 Strikingly, combined treatment with ATRA and TSA also induced differentiation of primary APL blasts harboring the PLZF-RARa fusion, a subset of APL resistant to ATRA alone. 3 Moreover, combination therapy using ATRA and the HDACI suberoylanilide hydroxamic acid (SAHA) improved survival in transgenic mouse models of APL, as compared with mice receiving either agent alone. 2 Clinical experience of use of HDACI in the management of patients with APL has been extremely limited; nevertheless, a response was documented in one patient with multiply relapsed ATRA-resistant disease following addition of the HDACI sodium phenylbutyrate. 4 Recently, sodium valproate, a well-established drug for the long-term management of epilepsy, has also been shown to inhibit HDAC activity at therapeutic concentration, promoting differentiation of hematopoietic cells expressing the PML-RARa fusion. 5 Moreover, in a more recent study, sodium valproate was shown to induce apoptosis through TRAIL and Fas signaling pathways of primary PML-RARA þ APL blasts in vitro and also in vivo, prolonging survival of APL transgenic mice. 6 Overall these data provide a strong rationale for evaluation of sodium valproate in the management of patients with APL, although to date, there have been no published reports of this agent in patients with this disease. The clinical investigation of HDACI in APL has focused on treatment of multiply relapsed resistant cases, in whom such an approach may be intrinsically less efficacious. 7 Given that maintenance therapy has been shown to reduce relapse risk in randomized studies, 1 it is possible that HDACI such as sodium valproate could be of value in the maintenance of remission of APL. We report a patient who was unable to have any further intensive chemotherapy for APL after her induction course and who has remained in molecular remission for 2.5 years, which we believe may be attributed to the HDACI sodium valproate.
A 29-year-old female presented on 16/8/02 (day 1) with a 4-week history of bleeding gums and bruising. Her Hb was 8.0 g/dl, WCC 2.7 Â 10 9 /l and platelets 9 Â 10 9 /l. Bone marrow demonstrated hypergranular APL, which was confirmed by the cytogenetic finding of t(15:17) and presence of PML-RARA fusion (bcr1 PML breakpoint). She was started on ATRA at a dose of 45 mg/m 2 per day on day 1. This was followed from day 5 by daunorubicin (total dose 150 mg/m 2 ) and cytarabine (total dose 2 g/m 2 ). On day 22, she suddenly deteriorated with hypoxia and required emergency intubation and transfer to intensive care. Blood counts by day 45 suggested that she was in complete remission (CR); because of her clinical condition a bone marrow confirming this was not done until day 101. By day 50 she was extubated but had a profound critical care myopathy with virtually no movement in her trunk, arms or legs. With intensive physiotherapy this has gradually recovered after many months.
On day 66, she developed status epilepticus due to electrolyte imbalance. This was treated with phenytoin and on day 68 sodium valproate was added to control her condition (400 mg i.v. loading dose, then 400 mg po b.i.d.). Sodium valproate levels were documented to be in the therapeutic range for epilepsy (51 mg/l) at day 107; however, the dose was increased to 400 mg po t.d.s. as she had further fits and has remained on this dose to the present day. The prolonged recovery period made it impossible to give further intensive chemotherapy. She was kept on ATRA until day 152 following documentation of molecular remission and then commenced on maintenance with 6-mercaptopurine (6-MP, 90 mg/m 2 /day orally), methotrexate (15 mg/m 2 /week orally) and ATRA (45 mg/m 2 /day, 15 days every 3 months). Maintenance chemotherapy had to be stopped intermittently due to neutropenia or nausea ( Figure 1 ) and dose reduced as required in line with neutropenia. She has since remained in molecular remission from APL, with the last marrow taken for MRD assessment on day 885 (Figure 1 ). Her disease was monitored molecularly throughout.
To date, studies of HDACI in APL have focused on relapsed resistant disease, which is characterized by a high incidence of acquired mutations in the ligand-binding domain (LBD) of PML-RARa conferring secondary retinoid resistance. 7 Although initial results were promising, 4 sodium phenylbutyrate proved ineffective in a further four patients. 7 Owing to the uncertainty of response to HDACI in the context of relapsed APL, it is possible that HDAC inhibition could provide a more effective therapeutic strategy if employed at an earlier stage in the disease course before LBD mutations are selected, possibly as a component of maintenance therapy as was effectively the case in the patient described here. Based on randomized trial data (reviewed in Mistry et al 1 ), combination therapy with ATRA, 6-MP and methotrexate has been adopted as standard maintenance therapy in APL. However, such regimens are commonly limited by neutropenia and therefore the use of nonmyelosuppressive HDACIs such as sodium valproate as a component of maintenance therapy in combination with ATRA merits further investigation.
Given the limited chemotherapy administered to the patient described here, the sustained profound molecular remission was both unexpected and encouraging, particularly as it has previously been shown that over 80% of patients who will ultimately relapse test PCR positive within 6 months of completion of chemotherapy. 8 Given the synergism between ATRA and HDAC inhibition demonstrated in vitro and in murine models of APL, it seems highly plausible that sodium valproate contributed to the favorable clinical outcome in this case, supporting the further evaluation of therapies targeting epigenetic change which could provide a novel approach to maintenance therapy in APL. given. Molecular response to therapy as determined by PML-RARA transcript copy numbers normalized to ABL copy numbers (bold blue line) in serial marrow samples taken over the treatment course. The sensitivity for each assay is calculated on the basis of ABL expression in the given sample and the difference in cycle threshold values (DCt) between PML-RARA and ABL at diagnosis, denoted by the dotted red line. Samples testing PCR positive are indicated by filled blue circles and PCR negative by white circles (for samples testing PCR negative, the sensitivity and normalized fusion gene copy number data points are superimposed). Almost a four-log reduction in normalized PML-RARA transcript level was documented over the first 3 months of therapy, with the patient testing PCR negative for the PML-RARA fusion on day 101 at a sensitivity of approximately 1 in 10
4 . Subsequent marrow samples tested negative for the PML-RARA fusion, with fluctuation in data points reflecting variation in maximal sensitivity achievable according to control gene expression at each respective time point. Comparable MRD data were obtained when PML-RARA transcript numbers were normalized to B2M as the control gene.
